Insider trade

Bridgebio Oncology Therapeutics (BBOT): Director received 32K units

Jake Bauer, Director at Bridgebio Oncology Therapeutics, reported a grant / award of 32K units.

32K
Derivative units
Traded
Jun 16, 2026
Filed
Jun 19, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Apr 20, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On April 20, 2026, the Board of Directors (the “Board”) of BridgeBio Oncology Therapeutics, Inc. (the “Company”) approved the appointment of Pedro Beltran, Ph.D., as the Company’s President and Chief Executive Officer (“CEO”) (and as the Company’s principal executive officer), effective immediately.”
  2. Apr 27, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.”
  3. May 12, 2026Company filing · Form 8-K · ResultsReported its results
  4. Jun 16, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 16, 2026, Michelle Doig notified BridgeBio Oncology Therapeutics, Inc. (the “Company”), of her resignation as a member of the Board of Directors of the Company (the “Board”) upon the completion of her term as a Class I director, effective as of June 16, 2026, the date of the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”

What came next

  1. Aug 11, 2026Company filing · Form 8-K · ResultsReported its results
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Bridgebio Oncology Therapeutics

For Bridgebio Oncology Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BBOT page.

How this filing works

Explore the data

Common questions

Which Bridgebio Oncology Therapeutics (BBOT) insider traded, and how much?

Jake Bauer, Director at Bridgebio Oncology Therapeutics, reported a grant / award of 32K units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Jun 16, 2026. Filed: Jun 19, 2026. That is 3 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Bridgebio Oncology Therapeutics recently?

For Bridgebio Oncology Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the BBOT page.

Does this mean BBOT stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Bridgebio Oncology Therapeutics

Everything OQRO holds on this company is on its BBOT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data